Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021
Histogen Inc. (NASDAQ: HSTO) announced the upcoming release of its financial results for Q3 2021, scheduled for November 10, 2021, after market closure.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Histogen Inc. (NASDAQ: HSTO) announced the upcoming release of its financial results for Q3 2021, scheduled for November 10, 2021, after market closure. The company specializes in developing first-in-class restorative therapeutics aimed at enhancing natural bodily repair processes. Utilizing hypoxia-induced multipotent cells, Histogen's technology platform addresses various therapeutic needs, including joint cartilage regeneration and soft tissue repair.
Details
News Market Reaction – HSTO
The recorded move for HSTO in the trading session of this news was -2.95%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the third quarter will be released after the close of market on Wednesday, November 10, 2021.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications, including joint cartilage regeneration, spinal disk repair, tendon, ligament and other soft tissue repair. For more information, please visit www.histogen.com.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.